SEC Form 4 · accession 0001358403-16-000207
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Moseley
Officer — Sr. VP and General Counsel
Period of report
Jun 2, 2016
Accepted (ET)
Jun 6, 2016 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2016 | M | 15,000 | $2.55 | A | 15,196 | D | |
| Common Stock | Jun 2, 2016 | S | 15,000 | $13.00 | D | 196 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.55 | Jun 2, 2016 | M | 15,000 | D | — | Dec 31, 2022 | Common Stock | 15,000 | 13,823 | D |
Explanation of responses
- F1Includes 99 shares acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2015.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015.
- F325% of the shares subject to the stock option vested and became exercisable on January 1, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.